{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:19:44Z","timestamp":1786933184943,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Wolfe Medical Research Chair in Pharmacogenomics"},{"name":"Canadian Institutes of Health Team Grant: Personalized Health","award":["FRN 178435"],"award-info":[{"award-number":["FRN 178435"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Transl Gastroenterol","Clinical and Translational Gastroenterology"],"abstract":"<jats:sec>\n                    <jats:title>INTRODUCTION:<\/jats:title>\n                    <jats:p>Interleukin-13 receptor alpha 2 (IL13RA2), triggering receptor expressed on myeloid cells-1 (TREM-1), and oncostatin M (OSM) may be associated with response to tumor necrosis factor-\u03b1 antagonists (TNFAs) in inflammatory bowel disease. We aimed to assess the direction of association between TNFA-induced clinical remission and IL13RA2 and TREM-1, respectively, and assess the value of combining biomarkers for identifying nonresponders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Plasma samples from a retrospective inflammatory bowel disease cohort were collected before TNFA start. Clinical remission at 1-year, surgery, hospitalization, adverse drug events, and TNFA discontinuation were assessed. IL13RA2 and TREM-1 concentrations were compared between those with and without 1-year clinical remission. OSM data were obtained from our previous cohort. Where significant, TREM-1 and IL23RA2 thresholds associated with clinical remission at 1-year were assessed using a receiver operating characteristic analysis. Significant biomarkers were combined using a linear discriminant analysis. The performance characteristics were assessed for individual biomarkers and biomarker combinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      In Crohn's disease (CD) (n = 95) and ulcerative colitis (UC) (n = 53), higher IL13RA2 concentrations, but not TREM-1, were found among those not achieving TNFA-associated clinical remission at 1-year (IL13RA2, CD,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001; UC,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0003). IL13RA2 thresholds, 4.554 ng\/mL (CD) and 6.117 ng\/mL (UC) separated those with and without clinical remission at 1-year (CD, area under the receiver-operating characteristic curve = 0.80, 95% CI = 0.71\u20130.90,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001; UC, area under the receiver-operating characteristic curve = 0.79, 95% CI = 0.66\u20130.91,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0005). In CD, combining IL13RA2 and OSM concentrations enhanced prediction accuracy compared with either biomarker alone and increased the identification of other important clinical outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>IL13RA2, but not TREM-1, was associated with TNFA response. In CD, its prediction accuracy improves when combined with OSM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.14309\/ctg.0000000000000960","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:00:49Z","timestamp":1769007649000},"page":"e00960","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Combining Cytokine-Related Biomarkers to Better Define Tumor Necrosis Factor-\u03b1 Antagonist Response in Inflammatory Bowel Disease: An Observational Cohort Study"],"prefix":"10.14309","volume":"17","author":[{"given":"Eryn","family":"Rooney","sequence":"first","affiliation":[{"name":"Department of Physiology and Pharmacology, Western University, London, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gio R.","family":"Dela Cruz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Pharmacology, Western University, London, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Ponich","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Gregor","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Chande","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie D.","family":"Beaton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Western University, London, Ontario, Canada;"},{"name":"Department of Medicine, Division of Clinical Pharmacology, Western University, London, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6568-1714","authenticated-orcid":false,"given":"Aze","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Western University, London, Ontario, Canada;"},{"name":"Department of Medicine, Division of Clinical Pharmacology, Western University, London, Ontario, Canada;"},{"name":"Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2]]},"reference":[{"issue":"21","key":"R1-20260224","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"R3-20260224","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3390\/ph16091272","article-title":"Pharmacological therapy in inflammatory bowel diseases: A narrative review of the past 90 years","volume":"16","author":"Imbrizi","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"R4-20260224","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: Definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"issue":"5","key":"R5-20260224","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat Med"},{"key":"R6-20260224","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ebiom.2019.01.027","article-title":"Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease","volume":"40","author":"Verstockt","year":"2019","journal-title":"EBioMedicine"},{"issue":"11","key":"R7-20260224","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/14728222.2019.1677608","article-title":"Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)","volume":"23","author":"Verstockt","year":"2019","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"R8-20260224","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/apt.15126","article-title":"Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease","volume":"49","author":"Verstockt","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"R9-20260224","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/gut.2009.178665","article-title":"Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis","volume":"58","author":"Arijs","year":"2009","journal-title":"Gut"},{"issue":"10","key":"R10-20260224","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1172\/JCI30602","article-title":"TREM-1\u2013expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases","volume":"117","author":"Schenk","year":"2007","journal-title":"J Clin Invest"},{"issue":"1","key":"R11-20260224","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12967-024-05058-1","article-title":"Predictive biomarkers for anti-TNF alpha therapy in IBD patients","volume":"22","author":"Kumar","year":"2024","journal-title":"J Transl Med"},{"key":"R12-20260224","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.3389\/fimmu.2018.02983","article-title":"Effects of epithelial IL-13R\u03b12 expression in inflammatory bowel disease","volume":"9","author":"Verstockt","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"R13-20260224","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41598-022-05208-9","article-title":"High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor \u03b1 antagonists","volume":"12","author":"Guo","year":"2022","journal-title":"Sci Rep"},{"issue":"8167","key":"R14-20260224","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet."},{"issue":"12","key":"R15-20260224","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"R16-20260224","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s43586-024-00346-y","article-title":"Linear discriminant analysis","volume":"4","author":"Zhao","year":"2024","journal-title":"Nat Rev Methods Primers"},{"issue":"4","key":"R17-20260224","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2222.2007.02921.x","article-title":"A novel and sensitive ELISA reveals that the soluble form of IL-13R-alpha2 is not expressed in plasma of healthy or asthmatic subjects","volume":"38","author":"O'Toole","year":"2008","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"R18-20260224","doi-asserted-by":"crossref","first-page":"7870","DOI":"10.4049\/jimmunol.0901028","article-title":"IL-13R alpha 2 membrane and soluble isoforms differ in humans and mice","volume":"183","author":"Chen","year":"2009","journal-title":"J Immunol (Baltimore, Md, 1950)"},{"issue":"2","key":"R19-20260224","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaci.2006.09.039","article-title":"Allergen-dependent solubilization of IL-13 receptor alpha2 reveals a novel mechanism to regulate allergy","volume":"119","author":"Daines","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"5-6","key":"R20-20260224","first-page":"313","article-title":"NFAT and AP1 are essential for the expression of a glioblastoma multiforme related IL-13Ra2 transcript","volume":"32","author":"Wu","year":"2010","journal-title":"Cell Oncol"},{"issue":"3","key":"R21-20260224","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11060-022-04196-0","article-title":"Plasma IL13R\u03b12 as a novel liquid biopsy biomarker for glioblastoma","volume":"160","author":"Khristov","year":"2022","journal-title":"J Neurooncol"},{"issue":"2","key":"R22-20260224","first-page":"101","article-title":"Interleukin 13 receptors as biochemical markers in atopic patients","volume":"21","author":"Hussein","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R23-20260224","doi-asserted-by":"crossref","first-page":"627535","DOI":"10.3389\/fimmu.2021.627535","article-title":"Monocyte TREM-1 levels associate with anti-TNF responsiveness in IBD through autophagy and Fc\u03b3-receptor signaling pathways","volume":"12","author":"Prins","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"R24-20260224","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/gutjnl-2018-316845","article-title":"TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?","volume":"68","author":"Verstockt","year":"2019","journal-title":"Gut"},{"issue":"4","key":"R25-20260224","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/gutjnl-2017-315494","article-title":"Cell-centred meta-analysis reveals baseline predictors of anti-TNF\u03b1 non-response in biopsy and blood of patients with IBD","volume":"68","author":"Gaujoux","year":"2019","journal-title":"Gut"}],"container-title":["Clinical and Translational Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.14309\/ctg.0000000000000960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:14:09Z","timestamp":1786547649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.14309\/ctg.0000000000000960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.14309\/ctg.0000000000000960","relation":{},"ISSN":["2155-384X"],"issn-type":[{"value":"2155-384X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"2025-08-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}